GlassScriptPhysician profile
Kala L Slaton
NPI 1568825354
$7,845.49
in general payments reported to CMS, 2019-2025
24 companies · $4,173 in 2025
The $4,173 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $970 · 2023: $424 · 2024: $1,629 · 2025: $4,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,100 · Travel and Lodging: $1,823 · Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,099.99 |
| Travel and Lodging | $1,822.97 |
| Food and Beverage | $1,303.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,577.20 | 2022-2025 | |
| Coloplast Corp | $591.13 | 2021-2024 | |
| Astellas Pharma US INC | $356.20 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $241.65 | 2022-2025 | |
| Pfizer INC. | $149.80 | 2022-2025 | |
| Biogen, INC. | $139.24 | 2024-2025 | Zurzuvae |
| Minerva Surgical, INC | $117.88 | 2022-2023 | |
| Abbvie INC. | $116.69 | 2022-2023 | Liletta, Lo Loestrin Fe |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.04 | 2021 | |
| Organon LLC | $76.80 | 2022-2024 | |
| Hologic Sales and Service, LLC | $61.26 | 2023 | Novasure |
| Exeltis, USA INC. | $55.02 | 2023-2025 | Slynd |
| Dexcom, INC. | $38.61 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $32.69 | 2023-2024 | Wegovy |
| Shield Therapeutics INC | $32.19 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $29.42 | 2024-2025 | Interstim |
| Therapeuticsmd, INC. | $25.87 | 2022 | |
| Lsi Solutions INC | $23.36 | 2023 | Fornisee |
| Millicent US INC | $23.18 | 2025 | Intrarosa, Femlyv |
| Smith+Nephew, INC. | $17.89 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.54 | 2022 | |
| Tela Bio, INC. | $15.94 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Bayer Healthcare Pharmaceuticals INC. | $15.89 | 2022 | |
| Evofem Biosciences, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Slaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.